• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

    5/27/25 8:01:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XOMA alert in real time by email

    EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million.

    "This transaction further builds the potential of XOMA Royalty's late-stage royalty portfolio by increasing our economics in a promising Phase 3 program already in our portfolio," stated Brad Sitko, Chief Investment Officer of XOMA Royalty.  "We appreciate the longstanding relationship with BioInvent stemming from XOMA's legacy technology, which gave rise to mezagitamab.  We are pleased to provide BioInvent non-dilutive capital to further advance its proprietary pipeline to a key inflection point."

    Martin Welschof, Chief Executive Officer of BioInvent said, "Today's announcement highlights the value to BioInvent of our n-CoDeR® platform, which has led to the identification of multiple promising therapeutic antibody drug candidates, many of which are now in mid-to late-stage clinical trials.  As well as reflecting XOMA Royalty's expanded interest in mezagitamab, this transaction supports our strategy of creating value via partnerships and gives us a non-dilutive capital injection that bolsters our balance sheet so that we can continue to focus on advancing our own clinical drug development programs."

    The future royalty and milestone economics interest in mezagitamab originated from a 2003 cross-licensing agreement covering XOMA Royalty's legacy bacterial protein expression technology and BioInvent's n-CoDeR® antibody library.  Under the terms of XOMA Royalty's purchase of BioInvent's economic interest in mezagitamab, XOMA Royalty paid USD $20 million to BioInvent at closing today and will pay an additional USD $10 million upon mezagitamab achieving a specific pre-defined regulatory milestone associated with receiving marketing approval in the IgA nephropathy indication from the U.S. Food and Drug Administration.  

    With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on future mezagitamab commercial sales.

    In its Fiscal Year 2024 financial results, Takeda, the company developing mezagitamab, announced it has initiated a Phase 3 clinical trial in patients with immune thrombocytopenia (ITP)1.  Mezagitamab is a fully human immunoglobulin IgG1 monoclonal antibody (mAb) with high affinity for CD38 expressing cells (including plasmablasts, plasma cells, natural killer cells) resulting in their depletion that has the potential of becoming the best-in-class anti-CD38 mAb2.

    About XOMA Royalty Corporation

    XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

    About BioInvent

    BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors.  The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

    The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

    XOMA Royalty Forward-Looking Statements/Explanatory Notes

    Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA Royalty and other developments related to mezagitamab.  In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will", "would," "could" or "should," the negative of these terms or similar expressions.  These forward-looking statements are not a guarantee of XOMA Royalty's performance, and you should not place undue reliance on such statements.  These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them.  Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission.  Consider such risks carefully when considering XOMA Royalty's prospects.  Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.  XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.

    EXPLANATORY NOTE: Any references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to "assets" in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

    As of the date of this press release, the commercial assets in XOMA Royalty's milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet).  All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.

    BioInvent disclaimer

    The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

    XOMA Royalty Investor contact:  XOMA Royalty Media contact:
    Juliane Snowden Kathy Vincent
    XOMA Royalty Corporation KV Consulting & Management
    +1-646-438-9754 +1-310-403-8951
    [email protected] [email protected]
       

    BioInvent Investor Contact:

    Cecilia Hofvander, VP Investor Relations

    Phone: +46 (0)46 286 85 50

    Email: [email protected]



    BioInvent International AB (publ)

    Co. Reg. No.: 556537-7263

    Visiting address: Ideongatan 1

    Mailing address: 223 70 LUND

    Phone: +46 (0)46 286 85 50

    www.bioinvent.com

    This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2025-05-27 14:00 CEST (8:00 am EDT).


    1 https://assets-dam.takeda.com/image/upload/v1746766844/Global/Investor/Financial-Results/FY2024/Q4/qr2024_q4_p01_en.pdf

    2 https://assets-dam.takeda.com/image/upload/Global/Investor/events/2024/RD_Presentation_2024_EN.pdf



    Primary Logo

    Get the next $XOMA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XOMA

    DatePrice TargetRatingAnalyst
    4/17/2025$35.00Buy
    The Benchmark Company
    4/29/2024$40.00Outperform
    Leerink Partners
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    9/7/2021$22.00Outperform → Neutral
    Wedbush
    9/7/2021$22.00Neutral → Underperform
    Wedbush
    6/29/2021$60.00Buy
    Aegis Capital
    More analyst ratings

    $XOMA
    SEC Filings

    View All

    SEC Form 8-K filed by XOMA Royalty Corporation

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    9/26/25 5:29:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    9/23/25 5:13:38 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by XOMA Royalty Corporation

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    8/15/25 4:00:49 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right ("CVR") per share representing the right to receive 75% of the net proceeds related to LAVA's two partnered assets and 75% of any net proceeds from any out license or sale of LAVA's unpartnered programs (the "Offer"). The Offer,

    10/2/25 4:43:26 PM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

    Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company. XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) continues to act as structuring agent and intends to provide financing for the transac

    9/24/25 6:00:00 AM ET
    $EPIX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

    WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural"), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the "Irish Takeover Rules"), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the "Proxy Statement") and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") and Mural entered into a definitive transaction

    9/23/25 7:52:56 PM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Sitko Bradley converted options into 6,712 shares, increasing direct ownership by 51% to 19,822 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:53 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Hughes Owen converted options into 35,567 shares, increasing direct ownership by 57% to 98,268 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:38 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance & CFO Burns Thomas M. sold $155,820 worth of shares (4,330 units at $35.99) and converted options into 11,846 shares, increasing direct ownership by 33% to 30,079 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:22 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on XOMA with a new price target

    Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00

    4/29/24 8:01:47 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on XOMA with a new price target

    HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously

    10/8/21 6:18:28 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/9/25 4:44:30 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/7/25 4:39:59 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

    Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

    5/9/24 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

    EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator.  I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated

    1/8/24 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

    SC 13G/A - XOMA Corp (0000791908) (Subject)

    2/9/24 10:05:21 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by XOMA Corporation (Amendment)

    SC 13D/A - XOMA Corp (0000791908) (Subject)

    1/16/24 5:22:40 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

    SC 13G/A - XOMA Corp (0000791908) (Subject)

    2/9/23 12:46:50 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right ("CVR") per share representing the right to receive 75% of the net proceeds related to LAVA's two partnered assets and 75% of any net proceeds from any out license or sale of LAVA's unpartnered programs (the "Offer"). The Offer,

    10/2/25 4:43:26 PM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:   Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about October 15, 2025, t

    9/22/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

    WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

    8/20/25 8:30:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care